Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
BNF presentation directory
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
Active filters
- Chemical substance: Paliperidone
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Paliperidone 150mg/1.5ml prolonged-release inj pf syringes
0402020ABAAADAD
|
Paliperidone (Injection) | Paliperidone | Central Nervous System | 1,511 |
|
Paliperidone 100mg/1ml prolonged-release inj pf syringes
0402020ABAAACAC
|
Paliperidone (Injection) | Paliperidone | Central Nervous System | 1,299 |
|
Paliperidone 75mg/0.75ml prolonged-release inj pf syringes
0402020ABAAABAB
|
Paliperidone (Injection) | Paliperidone | Central Nervous System | 754 |
|
Paliperidone 6mg modified-release tablets
0402010AEAAABAB
|
Paliperidone | Paliperidone | Central Nervous System | 519 |
|
Paliperidone 3mg modified-release tablets
0402010AEAAAAAA
|
Paliperidone | Paliperidone | Central Nervous System | 468 |
|
Paliperidone 50mg/0.5ml prolonged-release inj pf syringes
0402020ABAAAAAA
|
Paliperidone (Injection) | Paliperidone | Central Nervous System | 433 |
|
Paliperidone 9mg modified-release tablets
0402010AEAAACAC
|
Paliperidone | Paliperidone | Central Nervous System | 151 |
|
Xeplion 100mg/1ml prolonged-release inj pf syringes
0402020ABBBACAC
|
Xeplion | Paliperidone | Central Nervous System | 118 |
|
Xeplion 150mg/1.5ml prolonged-release inj pf syringes
0402020ABBBADAD
|
Xeplion | Paliperidone | Central Nervous System | 94 |
|
Xeplion 75mg/0.75ml prolonged-release inj pf syringes
0402020ABBBABAB
|
Xeplion | Paliperidone | Central Nervous System | 81 |
|
Paliperidone 525mg/2.625ml prolonged-release inj pf syringes
0402020ABAAAIAI
|
Paliperidone (Injection) | Paliperidone | Central Nervous System | 77 |
|
Paliperidone 350mg/1.75ml prolonged-release inj pf syringes
0402020ABAAAHAH
|
Paliperidone (Injection) | Paliperidone | Central Nervous System | 65 |
|
Trevicta 350mg/1.75ml prolonged-release inj pf syringes
0402020ABBCACAH
|
Trevicta | Paliperidone | Central Nervous System | 59 |
|
Paliperidone 263mg/1.315ml prolonged-release inj pf syringes
0402020ABAAAGAG
|
Paliperidone (Injection) | Paliperidone | Central Nervous System | 47 |
|
Trevicta 525mg/2.625ml prolonged-release inj pf syringes
0402020ABBCADAI
|
Trevicta | Paliperidone | Central Nervous System | 43 |
|
Xeplion 50mg/0.5ml prolonged-release inj pf syringes
0402020ABBBAAAA
|
Xeplion | Paliperidone | Central Nervous System | 37 |
|
Invega 3mg modified-release tablets
0402010AEBBAAAA
|
Invega | Paliperidone | Central Nervous System | 34 |
|
Paliperidone 175mg/0.875ml prolonged-release inj pf syringes
0402020ABAAAFAF
|
Paliperidone (Injection) | Paliperidone | Central Nervous System | 31 |
|
Invega 6mg modified-release tablets
0402010AEBBABAB
|
Invega | Paliperidone | Central Nervous System | 25 |
|
Trevicta 263mg/1.315ml prolonged-release inj pf syringes
0402020ABBCABAG
|
Trevicta | Paliperidone | Central Nervous System | 16 |
|
Trevicta 175mg/0.875ml prolonged-release inj pf syringes
0402020ABBCAAAF
|
Trevicta | Paliperidone | Central Nervous System | 15 |
|
Byannli 700mg/3.5ml prolonged-release inj pf syringes
0402020ABBDAAAK
|
Byannli | Paliperidone | Central Nervous System | 2 |
|
Invega 9mg modified-release tablets
0402010AEBBACAC
|
Invega | Paliperidone | Central Nervous System | 2 |
|
Paliperidone 700mg/3.5ml prolonged-release inj pf syringes
0402020ABAAAKAK
|
Paliperidone (Injection) | Paliperidone | Central Nervous System | 2 |
|
Paliperidone 1g/5ml prolonged-release inj pf syringes
0402020ABAAAJAJ
|
Paliperidone (Injection) | Paliperidone | Central Nervous System | 1 |
Why monitor BNF codes?
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Understand demand drivers
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.